Equity Overview
Price & Market Data
Price: $1.38
Daily Change: +$0.02 / 1.45%
Range: $1.24 - $1.45
Market Cap: $41,957,552
Volume: 31,096
Performance Metrics
1 Week: 21.20%
1 Month: 0.21%
3 Months: 15.32%
6 Months: -35.13%
1 Year: 24.59%
YTD: 19.10%
Company Details
Employees: 9
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.